Shanghai Junshi Biosciences Announces Nearly RMB 380 Million Capital Increase for Grit Biotechnology

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) disclosed that its subsidiary, Shanghai JunTop Biosciences Co., Ltd., together with a consortium of institutional investors, will increase their holdings in Beijing Grit Biotechnology Co., Ltd. The new capital injection totals RMB 380 million (≈ USD 55 million) and values Grit Bio at RMB 1.45 billion pre‑investment.

Investment Structure

Valuation Drivers

• Core Program Progress – Robust data from GT101 (Phase II) and GT201 (Phase I) TIL therapies.
• Early‑Stage Pipeline – Multiple pre‑clinical candidates with rapid development timelines.
• Market Position – First‑in‑class TIL drug in China, expanding into the global IL‑15 complex arena.

Grit Biotechnology’s Focus

• Tumor‑Infiltrating Lymphocyte (TIL) Technology – Engineered autologous T cells that recognize tumor‑specific antigens.
• GT101 Injection – First Chinese TIL product approved for registered clinical trials; now in pivotal Phase II.
• GT201 Injection – Global first membrane‑bound IL‑15 complex TIL; IND filings completed in China and the U.S., advancing to Phase I.

Strategic Implications

The capital raise positions Grit Bio to accelerate its clinical program, expand manufacturing capacity, and pursue additional regulatory approvals. For Junshi Biosciences, the move deepens its footprint in the burgeoning tumor immunotherapy market and strengthens synergies with its own biotech portfolio.

Market Outlook

China’s immuno‑oncology market is projected to surpass USD 10 billion by 2030, with TIL therapies gaining traction as a personalized, off‑the‑shelf alternative to CAR‑T. The new investment is poised to secure Grit Bio’s leadership in this high‑growth niche.-Fineline Info & Tech